Sanjay Singh

Gennova

Dr. Sanjay Singh is the Chief Executive Officer of Gennova Biopharmaceuticals Ltd, Pune, India, a biotechnology company dedicated to the development and commercialization of safe, efficacious and affordable bio-therapeutics.

After obtaining a PhD in Biochemistry from the Central Drug Research Institute (CDRI), Lucknow, India, Dr. Singh worked on malaria vaccine development first at the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India and then at the National Institute of Health (NIH), USA where he eventually headed the Antigen Research Section at the Malaria Vaccine Development Branch of the National Institutes of Allergy and Infectious Diseases (NIAID), NIH, USA. During his tenure at the NIH, he was successful in taking four recombinant vaccine candidates from gene to human clinical trials.

In 2006, he joined as the CEO of Gennova Biopharmaceuticals Ltd., which was then a startup biotechnology company. At Gennova, Dr. Singh’s leadership has facilitated the launch of various therapeutic life-saving biologics in the cardiovascular, renal care and oncology market. His focus on innovations in bio-manufacturing technologies has made the drugs affordable to the masses and today, under his guidance Gennova is the market leader in four of its products. Two of the biosimilars (Tenecteplase and Pegaspargase) launched were the first to be launched globally. Realizing the potential of the use of Tenecteplase for stroke, Dr. Singh pioneered its approval for acute ischemic stroke – the first time globally.